Project: HeartPace: Engineering the first biological Pacemaker for bradycardia patients
| Acronym | HeartPace (Reference Number: 114245) |
| Duration | 01/11/2020 - 01/11/2023 |
| Project Topic | HeartPace will deliver the first-ever biological pacemaker platform, based on adenoviral gene therapy, providing an improved alternative over electronic devices to treat bradycardia. To achieve this goal, we will develop a suite of novel technologies that can permanently restore and regenerate natural cardiac pacing. By the end of the project, we will provide i) a short-term pacemaker gene therapy ready to enter pre-CTA/IMPD studies and ii) proof-of-concept for long-term pacemaker gene therapy. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 13 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Academic Medical Center Amsterdam, part of Amsterdam UMC | Partner | Netherlands |
| 2 | Naason Science Inc. | Partner | Korea, Republic of |
| 3 | PacingCure B.V. | Coordinator | Netherlands |
| 4 | SIRION Biotech GmbH | Partner | Germany |
| 5 | Witten/Herdecke University | Partner | Germany |